Literature DB >> 16777274

Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.

Noriko Kojimahara1, Akiko Maeda, Tetsuo Kase, Naohito Yamaguchi.   

Abstract

The antigenic drift of influenza A (H3N2) virus in 2003-2004 necessitated a change in the vaccine from the A/Panama to the A/Wyoming strain for the 2004-2005 season. Using hemagglutination inhibition, we therefore tested antibodies in sera of 39 individuals (mean age 64.6 years) at the end of the 2003-2004 season for cross-reactivity to vaccine strains and H3N2 antigens subject to antigenic drift. Antibodies against both A (H3N2) Panama and Wyoming developed in 5/13 (38.5%) unvaccinated individuals, whereas, 22/26 (84.6%) vaccinees developed antibodies to Panama and 21/26 (80.8%) to Wyoming. None of these individuals suffered an influenza episode that season. The results suggest that the elderly might develop protective levels of cross-reactive A (H3N2) Wyoming HI antibodies following vaccination with the Panama strain. Such strains, like the ones included in the 2003-2004 influenza vaccine, might be expected to provide a broad-spectrum antibody response that could be effective even in the face of single season antigenic drift.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777274     DOI: 10.1016/j.vaccine.2006.05.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

3.  Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Michele Pellegrini; Gabriele Angiolelli; Silvia Majori; Annarosa Floreani; Marta Cecilia Busana; Chiara Bertoncello; Renzo Trivello
Journal:  Clin Dev Immunol       Date:  2010-03-29

Review 4.  Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.

Authors:  Giancarlo Icardi; Andrea Orsi; Antonella Ceravolo; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

5.  Effects of a Formula Containing Two Types of Prebiotics, Bifidogenic Growth Stimulator and Galacto-oligosaccharide, and Fermented Milk Products on Intestinal Microbiota and Antibody Response to Influenza Vaccine in Elderly Patients: A Randomized Controlled Trial.

Authors:  Shinya Nagafuchi; Taketo Yamaji; Akihiro Kawashima; Yukiko Saito; Takeshi Takahashi; Takayuki Yamamoto; Mitsuo Maruyama; Hiroyasu Akatsu
Journal:  Pharmaceuticals (Basel)       Date:  2015-06-18

6.  Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.

Authors:  Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2016-10-04

Review 7.  MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Authors:  Angelika Banzhoff; Michele Pellegrini; Giuseppe Del Giudice; Elena Fragapane; Nicola Groth; Audino Podda
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.